Small molecule · developed by Neumora Therapeutics
NMRA-323511 is an oral agent studied in Alzheimer's disease and in healthy elderly participants.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06546995 | Phase 1 | Alzheimer's Disease | Completed | NMRA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer's DiseaseHealthy Elderly
Updated Oct 25, 2026. Something wrong or missing? Report it on the NMRA page.
See NMRA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NMRA catalysts and pipeline →